The antibody to CTLA-4 has the following anti-tumour mechanisms: (1) modulation of tumour-specific immune effector cells, such as CD8+ T cells, to promote their clonal proliferation, (2) removal of Tregs to reduce inhibition of tumour-associated immune response [46]. Here, CD8A is linked to neoplasm.